Not FDA-approved2Evidence: Smaller human trialsHormones

CJC-12952

Also called CJC-1295 DAC1

Key takeaway

CJC-1295 is a lab-made 29-amino-acid analogue of growth hormone-releasing hormone (GHRH). FDA treats CJC-1295 and CJC-1295 with drug affinity complex (DAC) as two different active substances.3 It is not an FDA-approved drug. FDA’s 2024 evaluation found that none of five CJC-1295-related substances is a component of an FDA-approved drug, and FDA staff recommended against adding any of them to the list of substances pharmacies may use in compounding.3 Its human data come from small, short studies in healthy adults, and FDA found no data on effectiveness for growth hormone deficiency. A company stopped clinical trials in 2006 after a participant died.3 CJC-1295 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.6

CJC-1295 at a glance

What it isA synthetic analogue of growth hormone-releasing hormone, 29 amino acids long. A version with an added drug affinity complex (DAC) binds to albumin in the blood and lasts longer.3
FDA statusNot FDA-approved. FDA staff recommended in 2024 against adding any CJC-1295-related substance to the 503A compounding list, and FDA lists CJC-1295 among compounding substances that may present significant safety risks.1,3
Human evidenceSmall placebo-controlled studies in healthy adults that measured hormone levels. FDA identified no effectiveness data for growth hormone deficiency.3
Sport statusFDA’s 2024 evaluation notes that growth hormone secretagogues, including CJC-1295, are prohibited at all times on the World Anti-Doping Agency’s prohibited list.3
Evidence strengthSmaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned

What is CJC-1295?

CJC-1295 is a lab-made peptide of 29 amino acids modelled on growth hormone-releasing hormone (GHRH), the brain hormone that prompts the pituitary to release growth hormone.3

FDA’s evaluation distinguishes CJC-1295 from CJC-1295 with drug affinity complex (DAC), which carries an added chemical group that binds albumin in the blood. FDA treats them as different active substances, each with salt forms, and says they are not interchangeable.3

FDA reports that CJC-1295 DAC was first described in 2005 by ConjuChem Biotechnologies, and that interest in CJC-1295 on internet forums has grown since then.3

How is CJC-1295 thought to work?

As an analogue of GHRH, CJC-1295 is intended to stimulate the release of growth hormone. FDA states that published studies show CJC-1295 DAC acts as a growth hormone secretagogue in rodents, but it found no studies establishing whether CJC-1295 without DAC is pharmacologically active.3

FDA notes that the DAC modification is thought to extend the peptide’s life in the body by binding albumin, but could also cause it to bind other proteins and have off-target effects.3

What do human studies show?

FDA’s evaluation describes placebo-controlled studies in healthy adults, published in 2006, in which a CJC-1295 DAC substance raised growth hormone and IGF-1 levels for days after a single exposure.3

Across three published studies, FDA counted 63 healthy adults exposed to it, 87% of them men, and 73% received only one exposure. Reactions where it was given were most common; FDA also lists headache, reactions in which blood vessels widen, increased heart rate and low blood pressure.3

FDA describes reports that a 2006 Phase 2 trial in people with HIV lipodystrophy was stopped after a participant had a fatal heart attack, which the attending physician attributed to underlying coronary artery disease. The data from that trial have not been published.3

FDA found no data on effectiveness for growth hormone deficiency and no safety information in children.3

What the evidence base contains

  • Controlled human trial Two placebo-controlled studies in healthy adults published in 2006, in which most participants received one or a few exposures to a CJC-1295 DAC substance and growth hormone and IGF-1 levels were measured.3
  • Small, short, or incompletely reported human study FDA counted 63 healthy adults, 87% of them men, exposed to a CJC-1295 DAC substance across three published studies; 73% received a single exposure.3
  • Animal or laboratory research Animal studies in which a CJC-1295 DAC substance acted as a growth hormone secretagogue, and toxicology studies in rats and dogs that showed bleeding, inflammation and tissue death where it was given.3

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is CJC-1295 FDA-approved?

No. FDA’s evaluation, dated November 15, 2024, states that none of the five CJC-1295-related substances is a component of an FDA-approved drug, and that there is no United States Pharmacopeia monograph for any of them.3

FDA staff evaluated the five substances for the 503A bulks list, the list of substances that pharmacies may use in compounding, for growth hormone deficiency. They concluded that the balance of criteria weighs against adding any of them, citing poor characterization, unclear history of use, safety concerns from animal studies and a lack of effectiveness data.3

A Federal Register notice announced that FDA’s Pharmacy Compounding Advisory Committee would discuss CJC-1295-related substances at its December 4, 2024 meeting. FDA’s evaluation states that FDA will not issue a final determination until the committee’s input has been considered.3,4

FDA’s compounding safety-risk page, current as of April 22, 2026, lists CJC-1295 among substances whose nominations were withdrawn, citing possible immune reactions, impurities and serious adverse events including increased heart rate.1

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. CJC-1295 is not among them.5,6

Timeline

  1. CJC-1295 DAC is first described in the scientific literature, according to FDA’s evaluation.3
  2. ConjuChem withdraws CJC-1295 DAC from clinical trials after a participant’s death, according to FDA’s evaluation.3
  3. A Federal Register notice announces the December 4, 2024 advisory-committee meeting that will discuss CJC-1295-related substances.4
  4. FDA staff date their evaluation recommending against adding CJC-1295-related substances to the 503A bulks list.3
  5. FDA’s Pharmacy Compounding Advisory Committee meets to discuss CJC-1295-related substances.3,4
  6. FDA’s compounding safety-risk page, as last updated, lists CJC-1295 among withdrawn nominations with safety concerns.1

What is still unknown?

Whether CJC-1295 has any clinical benefit: FDA found no effectiveness data for growth hormone deficiency.3

Its long-term safety, which FDA says is unknown, and its safety in children, for which FDA found no information.3

What is in products sold under the name: FDA found inconsistent naming and notes that it is often unclear which form is meant.3

FDA’s final decision on the 503A list, which was not part of the sources reviewed through November 14, 2026.1,3

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for CJC-1295: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for CJC-1295 are the records PeptideScanner has selected and published, not every registration or paper about CJC-1295. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

Not FDA-approved; named as an unapproved new drug in a federal enforcement case. FDA staff recommended in 2024 against adding any CJC-1295-related substance to the 503A compounding list, and FDA lists CJC-1295 among substances that may present significant safety risks. CJC-1295 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗

Status sources checked through July 22, 2026. See status sources and coverage →

What do the reviewed human studies say?

Human evidence reviewed September 15, 2026 · Review version 2.

Review source snapshots checked September 15, 2026 · Integrity checked September 15, 2026.

Three selected reports examine a long-acting CJC-1295 preparation in healthy adults, including a serum-protein analysis. Hormone and protein measurements are distinct from patient benefit; publication count is not a count of independent cohorts.↗↗↗

What the reviewed sources report

The studies reported sustained growth hormone and IGF-I responses, including preserved hormone pulsatility. They do not establish clinical benefit for injury recovery, body composition or aging, or long-term safety.↗↗

What remains unresolved?

  • Which findings apply to the exact molecular form and formulation being discussed?↗↗
  • Do controlled studies demonstrate patient-important benefits and adequately assess longer-term harms?↗↗

Read study designs, results, limitations, and sources →

What does the official evidence assessment say?

FDA assessment dated November 15, 2024 · Read September 15, 2026 · Preserved version 1

FDA's dated evaluation of five CJC-1295-related bulk substances. The briefing distinguishes DAC and non-DAC forms and is an advisory-stage assessment, not a final compounding rule. FDA document ↗

Which human evidence applies?

FDA describes the published studies as short studies of DAC forms in healthy adults. It identifies the 2009 proteomic report as a subset of the earlier Ionescu and Frohman study, rather than an independent participant cohort. FDA pp. 40, 42 ↗

What adverse effects were reported?

FDA reports injection-site reactions, headache, flushing and transient blood-pressure changes in the early studies. Limited exposure in healthy adults cannot establish longer-term safety or safety in growth hormone deficiency. FDA pp. 40, 41, 42 ↗

Why the terminated trial matters

FDA cites anecdotal reports of a death during a terminated HIV-lipodystrophy trial and states that its results were unpublished. This is an agency account of those reports, not proof that CJC-1295 caused the death. FDA pp. 40 ↗

Scope, source pin and remaining work

This summarizes the agency's dated assessment. It is not an independent claim that no evidence exists worldwide or that the briefing is a final regulatory decision. Newer reports and formulation identities require separate screening.

Source: FDA evaluation of five CJC-1295-related bulk substances, November 15, 2024. SHA-256: 202fa022933ef27241c6e19f2156ca764854ccf4a7286e0fe1f1b6b56df39506.

Open versioned assessment data →

Reviews summarize selected studies; their scope and limitations are shown above.

Read the full Human Evidence Review

Supervised synthesis

What do selected human studies report about CJC-1295?

Manually reviewed September 15, 2026 · version 2

Browse all Human Evidence Reviews · Open preserved synthesis version 2 →

Three selected reports examine a long-acting CJC-1295 preparation in healthy adults, including a serum-protein analysis. Hormone and protein measurements are distinct from patient benefit; publication count is not a count of independent cohorts.123

Bottom line from this bounded source set

The studies reported sustained growth hormone and IGF-I responses, including preserved hormone pulsatility. They do not establish clinical benefit for injury recovery, body composition or aging, or long-term safety.12

Reviewed study record

Early pharmacology trials in healthy adults

Design

Two blinded randomized placebo-controlled studies assessed pharmacokinetics and hormone responses over 28 and 49 days.1

Population

Participants were healthy adults aged 21–61; the abstract does not state their total number.1

Outcomes reported

Growth hormone and IGF-I concentrations increased for several days. The report recorded no serious adverse reactions.1

Limitations

Short-term hormone changes are surrogate measurements. No serious reactions in these studies does not establish safety over longer exposure or in other populations.1

Reviewed study record

Growth-hormone pulsatility

Design

A before-and-after physiology study measured overnight hormone secretion before and one week after exposure.2

Population

The participants were healthy men aged 20–40; the abstract does not state their total number.2

Outcomes reported

Mean and trough growth hormone levels and IGF-I increased, while pulse frequency and magnitude were unchanged.2

Limitations

The report describes an albumin-binding preparation and physiological endpoints. It does not establish improvement in a clinical condition or comparative long-term safety.2

Reviewed study record

Exploratory serum-protein biomarkers

Design

A before-and-after serum analysis compared samples before exposure and one week afterward.3

Population

Eleven healthy young adult men contributed samples.3

Outcomes reported

The authors identified changes in several protein spots and an association between one spot and IGF-I levels. These were proposed biomarkers.3

Limitations

This small exploratory analysis measured proteins, not clinical benefit. The selected abstract alone does not establish participant overlap; the companion FDA assessment supplies that context.3

Reviewed source set

  1. PubMed · 16352683Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. ↗PubMed PMID 16352683 · EFetch XML reviewed 2026-09-15 · payload SHA-256 8d07b071e6897064b1be996b01a888f8a2961a1b5317f7666bf07d47bbd7c205
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1210/jc.2005-1536. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  2. PubMed · 17018654Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. ↗PubMed PMID 17018654 · EFetch XML reviewed 2026-09-15 · payload SHA-256 0d26a88a537d4d0bca90c505b245b9ef465515c23d1ac6bd0daf4bd04521e3fd
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1210/jc.2006-1702. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  3. PubMed · 19386527Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. ↗PubMed PMID 19386527 · EFetch XML reviewed 2026-09-15 · payload SHA-256 8f7cca895c4de4a1ec4e77c37b685ad5b17e3bbfc045452710822ef9684e4290
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/j.ghir.2009.03.001. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
Official-source readings

Official-source update

Reviewed 2026-09-19 · Preserved version 1

The tested substance may not match every marketed name

FDA’s December 2024 briefing considered several CJC-1295 and DAC forms separately. The limited clinical reports appeared to involve a DAC active moiety with incompletely specified form; other nominated forms lacked equivalent clinical information. FDA PDF pp. 46, 50 ↗

More findings and the sources behind them

Selected FDA advisory-briefing sections, not a final agency ruling. The source date identifies the committee meeting (July 23–24 for the 2026 packages), not a new approval or final decision.

Hormone changes in healthy adults did not establish treatment benefit

The reviewed reports involved healthy adults, not patients with growth-hormone deficiency, and did not measure key clinical outcomes such as body-composition change or height velocity. FDA did not consider them evidence of effectiveness for that condition. FDA PDF pp. 50 ↗

The safety sample was small and mostly short exposure

FDA described 63 exposed participants, predominantly men, with most receiving a single exposure. That evidence did not characterize long-term safety or pediatric use. FDA PDF pp. 46 ↗

Adverse events need careful attribution

The briefing describes injection-site and systemic reactions, including heart-rate and blood-pressure effects. It also discusses a death attributed to coronary disease in an unpublished trial account; the document does not prove CJC-1295 caused that death. FDA PDF pp. 46 ↗

What remains to be checked

  • Check subsequent advisory records and any final FDA action separately from the staff briefing.
  • Retrieve and appraise the original human reports and proposed formulation or route; agency search findings are dated and do not establish a complete worldwide literature review.
Source dates and review coverage

PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.

  • FDA cjc-1295 briefing for the December 2024 advisory meeting ↗

    Source dated 2024-12-04; retrieved 2026-09-19.

    • The tested substance may not match every marketed name · PDF pp. 46, 50 of 72
    • Hormone changes in healthy adults did not establish treatment benefit · PDF pp. 50 of 72
    • The safety sample was small and mostly short exposure · PDF pp. 46 of 72
    • Adverse events need careful attribution · PDF pp. 46 of 72

    SHA-256: 202fa022933ef27241c6e19f2156ca764854ccf4a7286e0fe1f1b6b56df39506

Open versioned findings and source records →

Research coverage and study families

Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.

Open machine-readable coverage and record decisions →

PubMed search

Primary reports of administered CJC-1295 in people, including pharmacology and secondary analyses; animal, cell, analytical-method, review and online-discourse records retained as exclusions from this human-administration subset. This is not a claim that excluded records have no information value.

33 retrieved · 3 included · 30 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

"CJC-1295"[Title/Abstract] OR "CJC 1295"[Title/Abstract]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:57:43.880352+00:00 · HTTP 200 · SHA-256 d66171b2fade48f7ab62f4de398f3b1db63defae675dccd44157eb81fa1aeb8b.

  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:57:45.199939+00:00 · HTTP 200 · SHA-256 6c403649a04ac82b5e0ae574a4f1707f0babe8ac597896fd55e6582848ff8c03.

  • Eligibility decisions use titles and abstracts from the pinned PubMed results; unavailable details remain unresolved rather than inferred.
  • Full-text appraisal, study-family reconciliation, registry history and broader alias/jurisdiction searches remain separate open work.

Showing 25 of 33 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. PubMed 19386527 — include: Original human administration or secondary human-sample report; full appraisal and study-family reconciliation are separate from this eligibility decision. FDA briefing PDF page 42 (printed page 38) identifies the eleven men in Sackmann-Sala 2009 as a subset of Ionescu and Frohman 2006; these reports are not independent cohorts. Study families: CJC-1295-2006-pulsatility-cohort. Official cohort relationship source ↗.
  2. PubMed 17018654 — include: Original human administration or secondary human-sample report; full appraisal and study-family reconciliation are separate from this eligibility decision. FDA briefing PDF page 42 (printed page 38) identifies the eleven men in Sackmann-Sala 2009 as a subset of Ionescu and Frohman 2006; these reports are not independent cohorts. Study families: CJC-1295-2006-pulsatility-cohort. Official cohort relationship source ↗.
  3. PubMed 16352683 — include: Original human administration or secondary human-sample report; full appraisal and study-family reconciliation are separate from this eligibility decision. Study families: CJC-1295-2006-ascending-studies-linkage-unresolved.
  4. PubMed 42578445 — exclude: Review or evidence overview; not an original report of CJC-1295 administration in people.
  5. PubMed 42395176 — exclude: Review or evidence overview; not an original report of CJC-1295 administration in people.
  6. PubMed 42160466 — exclude: Review or evidence overview; not an original report of CJC-1295 administration in people.
  7. PubMed 42123471 — exclude: Review or evidence overview; not an original report of CJC-1295 administration in people.
  8. PubMed 42021992 — exclude: Review or evidence overview; not an original report of CJC-1295 administration in people.
  9. PubMed 41966639 — exclude: Review or evidence overview; not an original report of CJC-1295 administration in people.
  10. PubMed 41880199 — exclude: Review or evidence overview; not an original report of CJC-1295 administration in people.
  11. PubMed 41490200 — exclude: Review or evidence overview; not an original report of CJC-1295 administration in people.
  12. PubMed 41476424 — exclude: Review or evidence overview; not an original report of CJC-1295 administration in people.
  13. PubMed 41138283 — exclude: Analytical assay or sample-preparation research; the inspected abstract does not report CJC-1295 administration in people.
  14. PubMed 38197510 — exclude: Analytical method with administration samples for other peptides; no CJC-1295 human administration reported in the inspected abstract.
  15. PubMed 37806509 — exclude: Analytical assay or sample-preparation research; the inspected abstract does not report CJC-1295 administration in people.
  16. PubMed 38716080 — exclude: Analytical method with administration samples for other peptides; no CJC-1295 human administration reported in the inspected abstract.
  17. PubMed 35298973 — exclude: Analytical assay or sample-preparation research; the inspected abstract does not report CJC-1295 administration in people.
  18. PubMed 34736642 — exclude: Analytical assay or sample-preparation research; the inspected abstract does not report CJC-1295 administration in people.
  19. PubMed 34665524 — exclude: Analytical assay or sample-preparation research; the inspected abstract does not report CJC-1295 administration in people.
  20. PubMed 32971474 — exclude: Analytical assay or sample-preparation research; the inspected abstract does not report CJC-1295 administration in people.
  21. PubMed 30938069 — exclude: Equine analytical or administration research, outside the human-administration subset.
  22. PubMed 30489688 — exclude: Equine analytical or administration research, outside the human-administration subset.
  23. PubMed 27710891 — exclude: Internet-forum research describes reported use and discourse, without independently verified CJC-1295 exposure or clinical treatment outcomes; retained as a possible separate non-official-source research lead.
  24. PubMed 26879649 — exclude: CJC-1295 administration described in rodents; the human administration example was a different GHRH product.
  25. PubMed 26771670 — exclude: Internet-forum research describes reported use and discourse, without independently verified CJC-1295 exposure or clinical treatment outcomes; retained as a possible separate non-official-source research lead.

ClinicalTrials.gov search

ClinicalTrials.gov API v2 identity-name search, complete retrieved records. Includes protocols, extensions, combinations and expanded access; these are not all efficacy trials or published outcomes.

1 retrieved · 1 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

CJC-1295 OR CJC1295

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:28:05.647574+00:00 · HTTP 200 · SHA-256 a50eedf204079232feaa329d0ac610aa3613cf658851114afdd9fa2c7f9f178b.

  • Registry identity screening is distinct from appraisal of posted results, protocol history and publication linkage.
  • Other registries and unregistered studies are outside this search.

Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. ClinicalTrials.gov NCT00267527 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT00267527.

FDA search

Exact active-ingredient terms in the openFDA Drugs@FDA endpoint, checked September 15. A zero result describes this indexed query only, not worldwide nonapproval or every FDA document.

0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

products.active_ingredients.name:"CJC-1295" OR products.active_ingredients.name:"CJC 1295"

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:54:12.039794+00:00 · HTTP 404 · SHA-256 57b1e7534d003e4246182162fd2469cdf038de39405056f44fc006715e5496da.

  • This query does not cover all FDA safety communications, labels, compounding proceedings or other regulatory systems.

Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    EMA search

    Local identity matching in the pinned EMA medicines metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.

    0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

    Search terms, record decisions and remaining work

    Case-insensitive word-boundary matching of reviewed identity terms: ["CJC-1295", "CJC 1295", "CJC1295"]

    Source retrievals and payload pins
    • Open the source endpoint ↗

      Retrieved 2026-09-15T08:34:22.905972+00:00 · HTTP 200 · SHA-256 a947c2b8a56ac2b92ec96156843f262f5e516f83b375d6791d67a8f6dc695729.

    • Complete source-document appraisal and national European sources remain open.
    • Zero identity matches apply only to these feed fields and terms.

    Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

      EMA search

      Local identity matching in the pinned EMA documents metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.

      0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

      Search terms, record decisions and remaining work

      Case-insensitive word-boundary matching of reviewed identity terms: ["CJC-1295", "CJC 1295", "CJC1295"]

      Source retrievals and payload pins
      • Open the source endpoint ↗

        Retrieved 2026-09-15T08:34:29.167460+00:00 · HTTP 200 · SHA-256 c0c68d7d77783e0355cbc75bdd04772e9acc163236fc68abcd794477c4c3d439.

      • Complete source-document appraisal and national European sources remain open.
      • Zero identity matches apply only to these feed fields and terms.

      Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

        EMA search

        Local identity matching in the pinned EMA orphans metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.

        0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

        Search terms, record decisions and remaining work

        Case-insensitive word-boundary matching of reviewed identity terms: ["CJC-1295", "CJC 1295", "CJC1295"]

        Source retrievals and payload pins
        • Open the source endpoint ↗

          Retrieved 2026-09-15T08:34:31.262344+00:00 · HTTP 200 · SHA-256 7448bf4e77e3345b3f3fbb7062c335d2302d8ea458a246bbe8256ce48aad2806.

        • Complete source-document appraisal and national European sources remain open.
        • Zero identity matches apply only to these feed fields and terms.

        Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

          Explore status sources, recent additions, and coverage gaps

          Living status brief

          What is the current status of CJC-1295?

          Not FDA-approved; named as an unapproved new drug in a federal enforcement case. FDA staff recommended in 2024 against adding any CJC-1295-related substance to the 503A compounding list, and FDA lists CJC-1295 among substances that may present significant safety risks. CJC-1295 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗

          The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.

          Evidence present

          What records are connected here?

          Evidence lanes
          2
          Source years
          8
          Drugs@FDA applications
          0

          These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

          Coverage gaps

          What remains unknown or unsupported?

          PeptideScanner currently has no selected clinical trial records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

          PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

          Explore the Evidence Map and record counts

          Evidence Map v1

          What kinds of records connect to CJC-1295?

          Compare collection coverage →

          This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

          10Selected dated records
          15Connected citations
          8Populated source years2010–2026
          2/4Record lanes present

          Registered human studies

          Trial composition

          0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.

          PubMed bibliography

          Publication composition

          1 of 9 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

          Publication typesJournal Article 1

          Bibliography fields unavailable here for 8 selected records; the records remain visible as metadata observations.

          Regulatory and publication surfaces

          What is structurally connected?

          Drugs@FDA applications
          0
          FDA Federal Register documents
          1
          DailyMed SPL versions
          0
          Canonical profile
          Published
          Profile structured data
          Published
          Linked dated records
          10

          Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

          Profile publication history and record counts
          Source records by collection · 10 dated records

          Research hub

          Explore the CJC-1295 evidence record

          Open all 10 records →
          10Dated records
          2Evidence types
          10Cited public sources
          8Source years

          Change ledger

          Recently changed for CJC-1295

          Open all 12 events →

          PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

          Profile updated

          CJC-1295 profile

          We added a plain-language reader guide with cited answers, re-checked FDA’s CJC-1295 evaluation and compounding safety-risk page, and noted that HHS’s October 30, 2026 draft enforcement-discretion policy does not include CJC-1295.

          PeptideScanner change date
          November 14, 2026
          Evidence lane
          Profile
          Record added

          Detection of CJC-1295 in Equine Plasma by ELISA.

          PubMed lists PMID 42876013 in Drug testing and analysis as Journal Article, with publication-date metadata of 2026-10-14 (day precision). PeptideScanner associated the retained record with the identity slug cjc-1295. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

          PeptideScanner change date
          November 14, 2026
          Cited source date
          October 15, 2026
          Evidence lane
          Literature metadata
          Correction

          CJC-1295 profile

          We clarified that CJC-1295 with DAC is a related, distinct active moiety rather than an interchangeable form. The FDA briefing describes five bulk substances; clinical findings must retain the studied form.

          PeptideScanner change date
          September 15, 2026
          Evidence lane
          Profile

          Official-source collections

          Source records for CJC-1295

          Open the full research atlas →

          Evidence types

          Coverage by source year

          Selected records span November 18, 2010 to October 15, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

          Continue exploring

          Profiles with overlapping source-year coverage

          Open the research atlas →

          These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

          Organizations and trial records named in cited sources

          Organizations named in cited records

          • U.S. Food and Drug Administration1
          • U.S. Department of Health and Human Services5
          Dated updates connected to this profile · 10

          Updates connected to this profile

          Open the full cross-source timeline →
          1. Literature metadata

            Detection of CJC-1295 in Equine Plasma by ELISA.↗

            PubMed lists PMID 42876013 in Drug testing and analysis as Journal Article, with publication-date metadata of 2026-10-14 (day precision). PeptideScanner associated the retained record with the identity slug cjc-1295. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

          2. Literature metadata

            PubMed record PMID 19386527↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 19386527 at 2026-07-30T18:28:26.873Z. PubMed recorded a metadata revision date of 2025-05-29 and an Entrez history date of 2009-04-24. PeptideScanner associated this retained record with the identity slug cjc-1295. These dates describe PubMed metadata history, not the article's original publication date.↗

          3. Regulatory

            Federal Register notice 2024-24828↗

            The Federal Register published notice 2024-24828, attributed to FDA and its parent HHS department, on 2024-10-25. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List,” and PeptideScanner's exact reviewed identity mapping connects the document to CJC-1295.↗

          4. Literature metadata

            PubMed record PMID 30938069↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 30938069 at 2026-07-30T20:34:12.987Z. PubMed recorded a metadata revision date of 2020-01-13 and an Entrez history date of 2019-04-03. PeptideScanner associated this retained record with the identity slug cjc-1295. These dates describe PubMed metadata history, not the article's original publication date.↗

          5. Literature metadata

            PubMed record PMID 30489688↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 30489688 at 2026-07-30T20:43:12.045Z. PubMed recorded a metadata revision date of 2019-12-10 and an Entrez history date of 2018-11-30. PeptideScanner associated this retained record with the identity slug cjc-1295. These dates describe PubMed metadata history, not the article's original publication date.↗

          6. Literature metadata

            PubMed record PMID 17018654↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 17018654 at 2026-07-30T21:09:06.872Z. PubMed recorded a metadata revision date of 2018-12-01 and an Entrez history date of 2006-10-05. PeptideScanner associated this retained record with the identity slug cjc-1295. These dates describe PubMed metadata history, not the article's original publication date.↗

          7. Literature metadata

            PubMed record PMID 16352683↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 16352683 at 2026-07-30T21:09:05.761Z. PubMed recorded a metadata revision date of 2018-12-01 and an Entrez history date of 2005-12-15. PeptideScanner associated this retained record with the identity slug cjc-1295. These dates describe PubMed metadata history, not the article's original publication date.↗

          8. Literature metadata

            PubMed record PMID 26771670↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 26771670 at 2026-07-30T21:35:57.020Z. PubMed recorded a metadata revision date of 2016-12-30 and an Entrez history date of 2016-01-16. PeptideScanner associated this retained record with the identity slug cjc-1295. These dates describe PubMed metadata history, not the article's original publication date.↗

          9. Literature metadata

            PubMed record PMID 21204297↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 21204297 at 2026-07-30T21:38:23.138Z. PubMed recorded a metadata revision date of 2016-05-11 and an Entrez history date of 2011-01-05. PeptideScanner associated this retained record with the identity slug cjc-1295. These dates describe PubMed metadata history, not the article's original publication date.↗

          10. Literature metadata

            PubMed record PMID 15817669↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 15817669 at 2026-07-30T22:26:16.765Z. PubMed recorded a metadata revision date of 2010-11-18 and an Entrez history date of 2005-04-09. PeptideScanner associated this retained record with the identity slug cjc-1295. These dates describe PubMed metadata history, not the article's original publication date.↗

          Citations

          Sources

          Coverage and sources →

          Numbered markers in the text point here. Each link opens the original public record.

          1. 1
            Certain bulk drug substances for use in compounding that may present significant safety risks ↗

            U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

          2. 2
            Nicholasville Compounding Pharmacy and Its Owner Plead Guilty to Unlawful Distribution of Prescription Drugs ↗

            U.S. Department of Justice · Official source · Source checked July 22, 2026

          3. 3
            FDA evaluation of five CJC-1295-related bulk substances, November 15, 2024 ↗

            U.S. Food and Drug Administration · Official source · Source checked September 15, 2026

          4. 4
            Federal Register notice 2024-24828 · published 2024-10-25 · Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List ↗

            Federal Register via GovInfo · Official source · Source checked August 21, 2026

          5. 5
            Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

            Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

          6. 6
            HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

            U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026